Načítá se...

Bortezomib for refractory immune-mediated thrombocytopenia purpura (ITP)

The treatment of refractory immune-mediated thrombocytopenia (ITP) can be challenging. This case report describes treatment of refractory ITP with bortezomib, a proteosome inhibitior. This strategy has been successful in relapsing thrombotic thrombocytopenic purpura, but is a novel therapeutic appro...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Am J Ther
Hlavní autoři: Beckman, Joan D., Rollins-Raval, Marian A., Raval, Jay S., Park, Yara A., Mazepa, Marshall, Ma, Alice
Médium: Artigo
Jazyk:Inglês
Vydáno: 2018
Témata:
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5753577/
https://ncbi.nlm.nih.gov/pubmed/29293474
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MJT.0000000000000517
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!